An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects With Irritable Bowel Syndrome.
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2016
At a glance
- Drugs Talnetant (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 30 Mar 2010 Additional locations [Netherlands] identified as reported by ClinicalTrials.gov.
- 20 May 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Oct 2005 to Oct 2004 as reported by Clinicaltrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History